Firehawk冠状动脉雷帕霉素靶向洗脱支架治疗糖尿病合并急性冠脉综合征患者的单中心研究

Firehawk coronary artery rapamycin targeted eluting stent for the treatment of patients with diabetes and acute coronary syndrome: a single-center study

目的对比探讨新型药物洗脱支架火鹰(Firehawk)支架及XIENCE V依维莫司支架在糖尿病合并急性冠脉综合征(ACS)群体中的有效性及安全性。方法回顾性分析2017年2月至2019年8月于陆军第八十二集团军医院心脏介入中心接受冠状动脉(冠脉)介入治疗的确诊ACS合并2型糖尿病患者62例。按单一接受不同支架种类分为接受Firehawk支架的Firehawk组(30例)及接受XIENCE V支架的XIENCE V组(32例)。对比观察两组患者介入治疗术后12个月内累积心血管不良事件发生情况。结果 XIENCE V组中男性28例,女性4例;年龄37~91岁,平均(59.9±13.1)岁;Firehawk组中男性19例,女性11例。年龄30~79岁,平均(60.4±11.9)岁。两组患者吸烟、高血压及高脂血症情况及实验室检查结果比较,差异均无统计学意义(P>0.05)。两组手术成功率均为100.0%;随访中仅XIENCE V组失访1例,总随访率为98.4%。12个月内心绞痛:Firehawk组发生1例(3.33%)和XIENCE V组1例(3.23%),非致死性心肌梗死发生率:Firehawk组1例(3.33%),XIENCE V组0例(0%);心源性死亡发生率:Firehawk组0例(0%),XIENCE V组升主动脉瘤破裂死亡1例(3.23%),累积主要心血管不良事件发生率:6.67%vs. 6.45%(P>0.05)。结论应用Firehawk支架治疗糖尿病合并急性冠脉综合征安全有效,在主要心脏不良事件发生率比较无明显差异,安全性及有效性不劣于XIENCE V支架。

Objective To compare the effectiveness and safety of the new drug-eluting stent Firehawk stent and XIENCE V everolimus stent in diabetic patients with acute coronary syndrome(ACS).Methods A retrospective analysis of 62 patients with diagnosed ACS and type 2 diabetes who received coronary intervention at the Cardiac Intervention Center of the 82 nd Army Hospital of the Army from February 2017 to August 2019.According to a single type of stent that received different stents,they were divided into the Firehawk group(30 cases)that received the Firehawk stent and the XIENCE V group(32 cases)that received the XIENCE V stent.The occurrence of cumulative cardiovascular adverse events within 12 months after interventional therapy was compared and observed.Results There were 28 males and 4 females in the XIENCE V group;they were 37-91 years old,with an average of(59.9±13.1)years old;there were 19 males and 11 females in the Firehawk group.The age ranged from 30 to 79 years old,with an average of(60.4±11.9)years old.There was no statistically significant difference between the two groups of patients in smoking,hypertension and hyperlipidemia,and the results of some laboratory tests(P>0.05).The surgical success rate of the two groups was 100.0%;during the follow-up process,only one case in the XIENCE V group was lost to follow-up,and the total follow-up rate was 98.4%.Angina pectoris within 12 months:1 case(3.33%)in the Firehawk group and 1 case(3.23%)in the XIENCE V group.The incidence of non-fatal myocardial infarction:1 case(3.33%)in the Firehawk group and 0 case in the XIENCE V group(0%);incidence of cardiac death:0 cases(0%)in the Firehawk group and 1 case(3.23%)from ascending aortic aneurysm rupture in the XIENCE V group.The cumulative incidence of major adverse cardiovascular events:6.67%and 6.45%(P>0.05).Conclusion The Firehawk stent is safe and effective in the treatment of patients with diabetes and acute coronary syndrome.There is no significant difference in the incidence of major adverse cardiac events.The safety and effectiveness are not inferior to the XIENCE V stent.